Drugs that inhibit the RAAS-system, i.e. angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor blockers (ARB), increase the levels of ACE2 and it has therefore been suggested that treatment with these drugs might affect the risk of COVID-19 following exposure to SARS-CoV-2. This evidence concerns the gene ACE2 and COVID-19.